Expression Pathology to ID Cancer Protein Biomarkers for Roche's Drug Development Pipeline

Under the terms of the deal, Expression Pathology will use its Liquid Tissue SRM technology to develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in FFPE tissue samples.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.